Evidence map›Paper›PMID 34931691›Full record

ArticleHistology and histopathology2022

Knockdown of circular RNA hsa_circ_0062270 suppresses the progression of melanoma via downregulation of CDC45.

Tian Hao, Yi Yang, Juan He, Jia Bai, Yongjian Zheng, Zhanpeng Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review
  2. Review
  3. Article
  4. Nanoparticles-Delivered Circular RNA Strategy as a Novel Antitumor Approach.International journal of molecular sciences · 2024
    Review
  5. Circular RNAs in Cell Cycle Regulation of Cancers.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tian Hao *Department of Dermatology, Beijing Younger Medical Cosmetic Hospital, Beijing, PR China.
Yi Yang *Department of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing, PR China.
Juan HeDepartment of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing, PR China.
Jia BaiDepartment of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing, PR China.
Yongjian ZhengDepartment of Dermatology, Beijing Younger Medical Cosmetic Hospital, Beijing, PR China.
Zhanpeng LuoDepartment of Orthopedic, The 8th Medical Center of Chinese PLA General Hospital, Beijing, PR China. luozhanpeng_12@126.com.
Chinese PLA General Hospital · CNBeijing Obstetrics and Gynecology Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough systemic therapies for melanoma have been improved, the 5-year survival rate of this aggressive cancer remains poor. It has been shown that hsa_circ_0062270 was upregulated in patients with melanoma. However, the relevant mechanism of hsa_circ_0062270 in the progression of melanoma remains unclear.

methodsThe CCK-8, EdU staining, flow cytometry, and transwell assays were used to determine the viability, proliferation, apoptosis and invasion in melanoma cells. An in vivo animal study was performed finally.

resultsThe level of hsa_circ_0062270 was significantly upregulated in melanoma cells. In addition, hsa_circ_0062270 knockdown markedly inhibited the viability, proliferation, invasion and promoted the apoptosis of melanoma cells. Cell division cycle protein 45 (CDC45) is the host gene of hsa_circ_0062270, and downregulation of hsa_circ_0062270 notably decreased the expression of CDC45 in melanoma cells. Rescue assays confirmed that hsa_circ_0062270 regulated the growth of melanoma cells through CDC45. Moreover, RIP analysis showed that hsa_circ_0062270 interacted with RNA-binding protein (RBP) EIF4A3. Furthermore, in vivo study indicated that knockdown of hsa_circ_0062270 inhibited the melanoma tumor growth in vivo.

conclusionsDownregulation of hsa_circ_0062270 can inhibit the progression of melanoma through downregulation of CDC45. Our findings provide biological mechanisms for the use of hsa_circ_0062270 as a biomarker for melanoma and potential therapeutic target.

Indexed as

MelanomaMicroRNAsAnimalsApoptosisCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansRNA, CircularCDC45 protein, humanCell Cycle ProteinsMicroRNAsRNA, Circular

Identifiers

PMID34931691
OpenAlexW4200058334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.